Sign up to save your podcasts
Or
Share The Long Run with Luke Timmerman
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Long Run with Luke Timmerman
By Timmerman ReportScience
Based on Podcast App listening data
The Long Run with Luke Timmerman episodes
- Ep160: Abe Ceesay on Precision NeuroscienceAbe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.1 hr 9 min
- Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell DiseaseJimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.1 hr 8 min
- Ep158: David Younger and Randolph Lopez on SynBio & AI for DiscoveryDavid Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.1 hr 1 min
- Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug DiscoveryVineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.57 min
- Ep156: David Liu on New Tools and Techniques for BiologyDavid Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.1 hr 53 min
- Ep155: Valerie Daggett on Early Detection, and Treatment, of Alzheimer'sValerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.1 hr 3 min
- Ep154: Robert Ang on CRISPR to Protect Bone Marrow & Attack CancerRobert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.1 hr 4 min
- Ep153: Rick Young on Studying Gene Expression for Drug DiscoveryRick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.1 hr 2 min
- Ep152: Jens Eckstein on Investing in Healthy AgingJens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.1 hr 6 min
- Ep151: Shelley Force Aldred and Nathan Trinklein on Bispecific Antibodies for CancerShelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.1 hr 4 min
About The Long Run with Luke Timmerman
From the publisher's feed
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Best of The Long Run with Luke Timmerman
Ranked by our users in the last 21 days
More shows like The Long Run with Luke Timmerman
Freakonomics Radio
32,056 Listeners
Odd Lots
1,981 Listeners
The a16z Show
1,088 Listeners
About Men Radio
15 Listeners
The Bio Report
39 Listeners
How I Built This with Guy Raz
30,175 Listeners
POP | TECH | JAM
78 Listeners
Strings and Things
5 Listeners
The Readout Loud
333 Listeners
The Journal.
6,070 Listeners
Biotech 2050 Podcast
62 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,186 Listeners
Business Of Biotech
84 Listeners
BioCentury This Week
35 Listeners
Raising Health
149 Listeners
Biotech Hangout
20 Listeners
The BioCentury Show
12 Listeners
The Workup
0 Listeners
Cheeky Pint
49 Listeners